Neogenomics
NeoGenomics Laboratories, a leading provider of cancer-focused genetic testing services, is headquartered in the United States. Founded in 2001, the company has established itself as a key player in the oncology diagnostics industry, with major operational regions across North America and Europe. NeoGenomics offers a comprehensive range of services, including molecular testing, pathology, and clinical trial support, distinguished by their commitment to innovation and accuracy. Their advanced testing capabilities, such as next-generation sequencing and liquid biopsy, set them apart in a competitive market. With a strong market position, NeoGenomics has achieved notable milestones, including partnerships with prominent healthcare institutions and a growing portfolio of proprietary tests. Their dedication to improving patient outcomes through precision medicine continues to drive their success in the evolving landscape of cancer diagnostics.
DitchCarbon Score
How does Neogenomics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neogenomics's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neogenomics's reported carbon emissions
In 2023, NeoGenomics, headquartered in the US, reported total carbon emissions of approximately 4,717,000 kg CO2e. This figure includes 536,000 kg CO2e from Scope 1 emissions and 4,181,000 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. Despite the significant emissions, NeoGenomics has not established specific reduction targets or initiatives as part of their climate commitments. The absence of such targets suggests a need for further development in their sustainability strategy. As the company continues to operate within the healthcare sector, addressing carbon emissions will be crucial for aligning with industry standards and expectations regarding climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 536,000 |
| Scope 2 | 4,181,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neogenomics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
